EDAP TMS (EDAP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 May, 2026Executive summary
Ordinary and Extraordinary General Meeting scheduled for June 26, 2026, in Vaulx-en-Velin, France.
Shareholders are invited to vote on a comprehensive agenda covering director renewals, financial approvals, compensation, capital structure, and bylaw amendments.
Voting matters and shareholder proposals
Proposals include renewal of director terms, ratification of a temporary director, and approval of related-person agreements.
Approval of statutory and consolidated financial statements for the year ended December 31, 2025.
Advisory votes on executive compensation and frequency of future say-on-pay votes.
Multiple delegations of authority to the Board for capital increases, with or without preferential subscription rights, including for specific categories of investors and the European Investment Bank.
Amendments to bylaws regarding share capital, Board of Directors, and Shareholders' Meeting.
Board of directors and corporate governance
Renewal of terms for five directors and ratification of a temporary director appointed in February 2026.
Amendments proposed to bylaws affecting the Board of Directors.
Latest events from EDAP TMS
- 2025 featured significant HIFU milestones, a €25.9M net loss, and new EIB financing.EDAP
Proxy filing14 May 2026 - Record HIFU growth, expanded indications, and broad capital authorizations headline 2026 proxy.EDAP
Proxy filing14 May 2026 - Record Q1 revenue and 78% HIFU growth offset by higher net loss and cash outflow.EDAP
Q1 202613 May 2026 - Record HIFU growth, new EIB financing, and 32 key resolutions headline the 2026 proxy.EDAP
Proxy filing1 May 2026 - Up to $125 million in shares and warrants registered for flexible future offerings.EDAP
Registration filing27 Mar 2026 - Up to $125 million in securities offered, with EIB holding major warrants and broad use of proceeds.EDAP
Registration filing25 Mar 2026 - Record HIFU growth and Focal One adoption drive strong 2026 outlook despite wider net loss.EDAP
Q4 202525 Mar 2026 - Focal One HIFU is transforming prostate cancer care with superior outcomes and rapid adoption.EDAP
Oppenheimer 36th Annual Healthcare MedTech & Services Conference18 Mar 2026 - Record revenue and strong HIFU growth offset by lower margins and higher losses.EDAP
Q2 202423 Jan 2026